^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DLD overexpression

    i
    Other names: DLD, Dihydrolipoamide Dehydrogenase, OGDC-E3, DLDH, GCSL, LAD, E3, E3 Component Of Pyruvate Dehydrogenase Complex, 2-Oxo-Glutarate Complex, Branched Chain Keto Acid Dehydrogenase Complex, Dihydrolipoyl Dehydrogenase, Mitochondrial, Glycine Cleavage System L Protein, PHE3, Dihydrolipoamide Dehydrogenase (E3 Component Of Pyruvate Dehydrogenase Complex, 2-Oxo-Glutarate Complex, Branched Chain Keto Acid Dehydrogenase Complex), Epididymis Secretory Sperm Binding Protein, Glycine Cleavage System Protein L, Lipoamide Dehydrogenase, Lipoyl Dehydrogenase, Lipoamide Reductase, Diaphorase, DLDD
    Entrez ID:
    1738
    almost2years
    Multi-omics analysis reveals the unique landscape of DLD in the breast cancer tumor microenvironment and its implications for immune-related prognosis. (PubMed, Comput Struct Biotechnol J)
    Our findings underscore the significant predictive significance of DLD in BC and its influence on the tumor microenvironment. DLD represents a promising diagnostic and prognostic marker for BC, offering novel avenues for the identification of therapeutic targets and the enhancement of immunotherapy in BC.
    Journal • BRCA Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRCA (Breast cancer early onset) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • DLD (Dihydrolipoamide Dehydrogenase)
    |
    DLD overexpression